News
-
According to Kenox Pharmaceuticals, the company “received a positive response supporting the planned CMC, non-clinical and clinical development strategy” following a pre-IND meeting with FDA regarding the company’s KNX018 inhaled sensitizer for use with radiation… Read more . . .
-
US-based non-profit biotech Infectious Disease Research Institute (IDRI) said that it has received a 2-year contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of an intranasal RNA vaccine against influenza as part… Read more . . .
-
Nebulizer maker Aerogen and CanSino Biologics have signed a development and commercial supply deal for the use of Aerogen’s vibrating mesh nebulizer technology for delivery of CanSinoBIO’s Convidecia inhaled vaccine against COVID-19. Terms of the… Read more . . .
-
OINDP contract research and development company Nanopharm, a subsidiary of Aptar Pharma, has announced plans to move to a 25,000 sq ft building in Cwmbran, Wales that will house brand new R&D space and cGMP… Read more . . .
-
McMaster University announced that Health Canada has cleared a Phase 1 trial of two inhaled adenovirus vector vaccines against SARS-CoV-2, and the study is set to begin shortly. The trial is expected to enroll at… Read more . . .
-
Inhaled drug developer Aerami Therapeutics has announced that it will go public through a merger with a special purpose acquisition company (SPAC) called FoxWayne Enterprises Acquisition Corp., and the resulting company’s common stock will be… Read more . . .
-
The Cystic Fibrosis Foundation announced that it is providing $3.5 million for a Phase 2 study of Pulmocide Ltd’s PC945 inhaled opelconazole for the prevention of pulmonary Aspergillus infections following lung transplantation. The CF Foundation noted… Read more . . .
-
Biohaven Pharmaceutical said that a Phase 3 trial of its intranasal zavegepant (BHV-3500) for the treatment of moderate or severe migraine has met its primary endpoints, demonstrating statistically significant increase in freedom from both pain and… Read more . . .
-
Lupin announced that it has acquired exclusive global rights to soft mist inhalation technology developed by Cambridge, UK design company TTP, and the two companies will co-develop the SMI device for delivery of inhaled drugs.… Read more . . .
-
Inhaled nitric oxide developer Beyond Air announced that pulmonologist Andrew Colin has been appointed as the company’s Chief Medical Officer, effective December 1, 2021. Colin, who was most recently Chief of the Division of Pediatric… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan